Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	11.04	23.29	9.56	19.87	35.7	57.17
Cash & Short-Term Investments	11.04	23.29	9.56	19.87	35.7	57.17
Cash Growth	-57.32%	143.48%	-51.85%	-44.36%	-37.54%	438.55%
Prepaid Expenses	1.58	0.96	0.89	0.66	0.87	0.77
Total Current Assets	12.62	24.25	10.45	20.53	36.57	57.94
Property, Plant & Equipment	1.05	1.19	1.59	0.98	0.55	0.64
Other Long-Term Assets	0.03	0.03	0.03	0.08	0.08	0.08
Total Assets	13.7	25.47	12.08	21.59	37.2	58.66
Accounts Payable	4.68	4.11	9.18	2.56	1.41	1.43
Accrued Expenses	-	3.48	-	2.91	2.44	2.01
Current Portion of Leases	0.09	0.08	0.06	0.05	0.14	0.12
Other Current Liabilities	1.1	1.72	16.12	5.98	-	-
Total Current Liabilities	5.87	9.39	25.36	11.5	3.99	3.56
Long-Term Leases	0.36	0.41	0.49	0.55	0.17	0.3
Total Liabilities	6.23	9.8	25.85	12.05	4.16	3.86
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	264.96	261.12	182.92	168.14	182.56	161.53
Retained Earnings	-259.39	-247.34	-202.76	-159.99	-150.9	-126.78
Total Common Equity	5.56	13.77	-19.84	8.15	31.66	34.76
Shareholders' Equity	7.47	15.68	-13.78	9.54	33.05	54.79
Total Liabilities & Equity	13.7	25.47	12.08	21.59	37.2	58.66
Total Debt	0.45	0.49	0.55	0.6	0.3	0.42
Net Cash (Debt)	10.59	22.79	9.01	19.26	35.4	56.74
Net Cash Growth	-58.21%	152.94%	-53.22%	-45.59%	-37.61%	462.53%
Net Cash Per Share	7.23	18.41	22.12	81.90	191.31	859.21
Filing Date Shares Outstanding	3.19	1.54	1.08	0.32	0.2	0.17
Total Common Shares Outstanding	1.81	1.54	0.69	0.31	0.2	0.15
Working Capital	6.75	14.86	-14.91	9.03	32.58	54.38
Book Value Per Share	3.07	8.97	-28.69	26.06	155.46	229.47
Tangible Book Value	5.56	13.77	-19.84	8.15	31.66	34.76
Tangible Book Value Per Share	3.07	8.97	-28.69	26.06	155.46	229.47
Machinery	-	-	-	0.8	0.58	0.45
Leasehold Improvements	-	-	-	0.31	0.31	0.31

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q